FDA Clearance Tracker · P190022-S001
4Kscore Test
Last checked: Nov 20, 2026Latest source record: Jan 8, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jan 8, 2024
Approved
Time to decision
137 days
Received Aug 24, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P190022-S001
- Device name
- 4Kscore Test
- Applicant
- Opko Health, Inc.
- Applicant location
- Miami, FL
- Received
- Aug 24, 2023
- Decided
- Jan 8, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P190022
Device type
- Device type
- Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to transfer the manufacturing site for the preparation of two (iPSA and hK2) of the four 4Kscore Test reagents from the original site, OPKO Diagnostics, LLC., Woburn, Massachusetts, to a new manufacturing site, BioReference Health, LLC., Elmwood Park, New Jersey (BioReference).
Source documents
Other decisions for Opko Health, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- 4Kscore TestPMA
P190022 · Decided Dec 7, 2021 · 823 days after receipt
Device type: Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.